Core Viewpoint - Rosen Law Firm is encouraging investors of Telix Pharmaceuticals Ltd. to secure legal counsel before the January 9, 2026 deadline for a securities class action lawsuit related to the company's performance during the specified class period [1][2]. Group 1: Class Action Details - The class period for the securities class action is from February 21, 2025, to August 28, 2025 [1]. - Investors who purchased Telix securities during this period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and those wishing to serve as lead plaintiff must act by January 9, 2026 [3]. Group 2: Legal Representation - Investors are advised to select qualified legal counsel with a proven track record in securities class actions, as many firms may lack the necessary experience and resources [4]. - The Rosen Law Firm has a history of significant settlements, including the largest securities class action settlement against a Chinese company, and has recovered hundreds of millions for investors [4]. Group 3: Allegations Against Telix Pharmaceuticals - The lawsuit alleges that Telix's defendants made materially false and misleading statements regarding the progress of prostate cancer therapeutic candidates and the quality of its supply chain [5]. - It is claimed that these misrepresentations led to damages for investors when the true information became public [5].
ROSEN, NATIONAL TRIAL LAWYERS, Encourages Telix Pharmaceuticals Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - TLX